The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Persistent Cancer Cells: The Deadly Survivors
Open accessAbstract
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenotypic plasticity. Mechanisms that underlie their persistence offer highly coveted and sought-after therapeutic targets, and include diverse epigenetic, transcriptional, and translational regulatory processes, as well as complex cell-cell interactions. Although the successful clinical targeting of persistent cancer cells remains to be realized, immense progress has been made in understanding their persistence, yielding promising preclinical results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Definitions and guidelines for research on antibiotic persistence
Balaban, N. Q., Helaine, S., Lewis, K., Ackermann, M., Aldridge, B., Andersson, D. I., Brynildsen, M. P., Bumann, D., Camilli, A., Collins, J. J., et al. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0196-3 · Cited by 1,313
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Li, G.-W., Burkhardt, D., Gross, C., & Weissman, J. S. (2014) · Cell · doi:10.1016/j.cell.2014.02.033 · Cited by 1,251
Multistep Nature of Metastatic Inefficiency
Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N., Morris, V. L., Chambers, A. F., & Groom, A. C. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65628-3 · Cited by 1,243
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Mechanisms of disseminated cancer cell dormancy: an awakening field
Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3793 · Cited by 1,126
Metabolic regulation of cell growth and proliferation
Zhu, J., & Thompson, C. B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0123-5 · Cited by 1,116
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine
Moya, I. M., & Halder, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0086-y · Cited by 981
Mechanisms of bacterial persistence during stress and antibiotic exposure
Harms, A., Maisonneuve, E., & Gerdes, K. (2016) · Science · doi:10.1126/science.aaf4268 · Cited by 919
Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0441 · Cited by 912
Forcing cells to change lineages
Graf, T., & Enver, T. (2009) · Nature · doi:10.1038/nature08533 · Cited by 899
Lymph protects metastasizing melanoma cells from ferroptosis
Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., Gu, Z., McCormick, M. L., Durham, A. B., Spitz, D. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2623-z · Cited by 896
Au Yeung, C. L., Co, N.-N., Tsuruga, T., Yeung, T.-L., Kwan, S.-Y., Leung, C. S., Li, Y., Lu, E. S., Kwan, K., Wong, K.-K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11150 · Cited by 774
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
A Nonapoptotic Cell Death Process, Entosis, that Occurs by Cell-in-Cell Invasion
Overholtzer, M., Mailleux, A. A., Mouneimne, G., Normand, G., Schnitt, S. J., King, R. W., Cibas, E. S., & Brugge, J. S. (2007) · Cell · doi:10.1016/j.cell.2007.10.040 · Cited by 748
Simon, J. A., & Kingston, R. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.013 · Cited by 733
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
The Ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease
Nieto, M. A. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154036 · Cited by 720
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
Stress-Induced Mutagenesis in Bacteria
Bjedov, I., Tenaillon, O., Gérard, B., Souza, V., Denamur, E., Radman, M., Taddei, F., & Matic, I. (2003) · Science · doi:10.1126/science.1082240 · Cited by 587
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E. (2017) · Nature Medicine · doi:10.1038/nm.4399 · Cited by 546
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4055 · Cited by 528
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506
Lee, J.-K., Lee, J., Kim, S., Kim, S., Youk, J., Park, S., An, Y., Keam, B., Kim, D.-W., Heo, D. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9096 · Cited by 505
Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01585 · Cited by 500
The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway
Hong, W., & Guan, K.-L. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.05.004 · Cited by 493
Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity
Vriens, K., Christen, S., Parik, S., Broekaert, D., Yoshinaga, K., Talebi, A., Dehairs, J., Escalona-Noguero, C., Schmieder, R., Cornfield, T., et al. (2019) · Nature · doi:10.1038/s41586-019-0904-1 · Cited by 477
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70454 · Cited by 457
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Migden, M. R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., Combemale, P., Herd, R. M., Kudchadkar, R., Trefzer, U., Gogov, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70100-2 · Cited by 440
Lou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Bohn, T., Rapp, S., Luther, N., Klein, M., Bruehl, T.-J., Kojima, N., Aranda Lopez, P., Hahlbrock, J., Muth, S., Endo, S., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0226-8 · Cited by 436
Adaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.001 · Cited by 419
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386
Guo, J. Y., Teng, X., Laddha, S. V., Ma, S., Van Nostrand, S. C., Yang, Y., Khor, S., Chan, C. S., Rabinowitz, J. D., & White, E. (2016) · Genes & Development · doi:10.1101/gad.283416.116 · Cited by 372
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Vinogradova, M., Gehling, V. S., Gustafson, A., Arora, S., Tindell, C. A., Wilson, C., Williamson, K. E., Guler, G. D., Gangurde, P., Manieri, W., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2085 · Cited by 351
Macrophage-Associated PGK1 Phosphorylation Promotes Aerobic Glycolysis and Tumorigenesis
Zhang, Y., Yu, G., Chu, H., Wang, X., Xiong, L., Cai, G., Liu, R., Gao, H., Tao, B., Li, W., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.023 · Cited by 348
Distinctive properties of metastasis-initiating cells
Celià-Terrassa, T., & Kang, Y. (2016) · Genes & Development · doi:10.1101/gad.277681.116 · Cited by 336
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth, K., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. W. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12498 · Cited by 318
Park, J. H., Vithayathil, S., Kumar, S., Sung, P.-L., Dobrolecki, L. E., Putluri, V., Bhat, V. B., Bhowmik, S. K., Gupta, V., Arora, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.004 · Cited by 313
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells
Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Non-Darwinian dynamics in therapy-induced cancer drug resistance
Pisco, A. O., Brock, A., Zhou, J., Moor, A., Mojtahedi, M., Jackson, D., & Huang, S. (2013) · Nature Communications · doi:10.1038/ncomms3467 · Cited by 297
Cell-to-cell variation in p53 dynamics leads to fractional killing.
Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.025 · Cited by 292
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277
Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Takahashi, N., Chen, H.-Y., Harris, I. S., Stover, D. G., Selfors, L. M., Bronson, R. T., Deraedt, T., Cichowski, K., Welm, A. L., Mori, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.001 · Cited by 271
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
Yan, F., Al-Kali, A., Zhang, Z., Liu, J., Pang, J., Zhao, N., He, C., Litzow, M. R., & Liu, S. (2018) · Cell Research · doi:10.1038/s41422-018-0097-4 · Cited by 235
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells
Risson, E., Nobre, A. R., Maguer-Satta, V., & Aguirre-Ghiso, J. A. (2020) · Nature Cancer · doi:10.1038/s43018-020-0088-5 · Cited by 230
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Feng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., del Genio, C., Canfield, K., DiRenzo, J., Wells, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.008 · Cited by 216
Fox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0191-z · Cited by 210
Antibiotic treatment enhances the genome-wide mutation rate of target cells
Long, H., Miller, S. F., Strauss, C., Zhao, C., Cheng, L., Ye, Z., Griffin, K., Te, R., Lee, H., Chen, C.-C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601208113 · Cited by 208
Framework models of tumor dormancy from patient-derived observations
Klein, C. A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.011 · Cited by 207
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
Tumor-induced stromal reprogramming drives lymph node transformation
Riedel, A., Shorthouse, D., Haas, L., Hall, B. A., & Shields, J. (2016) · Nature Immunology · doi:10.1038/ni.3492 · Cited by 204
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R. W., Hagmann, J., Hess, C., & Christofori, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.028 · Cited by 197
Tumor cell–organized fibronectin maintenance of a dormant breast cancer population
Barney, L. E., Hall, C. L., Schwartz, A. D., Parks, A. N., Sparages, C., Galarza, S., Platt, M. O., Mercurio, A. M., & Peyton, S. R. (2020) · Science Advances · doi:10.1126/sciadv.aaz4157 · Cited by 175
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174
Beaver, J. A., Hazarika, M., Mulkey, F., Mushti, S., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 171
Li, S., Song, Y., Quach, C., Guo, H., Jang, G.-B., Maazi, H., Zhao, S., Sands, N. A., Liu, Q., In, G. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09634-8 · Cited by 165
Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs)
Bartosh, T. J., Ullah, M., Zeitouni, S., Beaver, J., & Prockop, D. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612290113 · Cited by 164
Sharma, A., Cao, E. Y., Kumar, V., Zhang, X., Leong, H. S., Wong, A. M. L., Ramakrishnan, N., Hakimullah, M., Teo, H. M. V., Chong, F. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07261-3 · Cited by 161
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 151
Evaluating evolutionary models of stress-induced mutagenesis in bacteria
MacLean, R. C., Barceló, C. T., & Moxon, R. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3415 · Cited by 150
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Sánchez-Danés, A., Larsimont, J.-C., Liagre, M., Muñoz-Couselo, E., Lapouge, G., Brisebarre, A., Dubois, C., Suppa, M., Sukumaran, V., del Marmol, V., et al. (2018) · Nature · doi:10.1038/s41586-018-0603-3 · Cited by 139
A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
Biehs, B., Dijkgraaf, G. J. P., Piskol, R., Alicke, B., Boumahdi, S., Peale, F., Gould, S. E., & de Sauvage, F. J. (2018) · Nature · doi:10.1038/s41586-018-0596-y · Cited by 137
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
Bakshi, A., Chaudhary, S. C., Rana, M., Elmets, C. A., & Athar, M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22690 · Cited by 135
Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0253 · Cited by 130
Culviner, P. H., & Laub, M. T. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.04.026 · Cited by 128
Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival
Tonnessen-Murray, C. A., Frey, W. D., Rao, S. G., Shahbandi, A., Ungerleider, N. A., Olayiwola, J. O., Murray, L. B., Vinson, B. T., Chrisey, D. B., Lord, C. J., et al. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201904051 · Cited by 127
DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk
Xie, W., Kagiampakis, I., Pan, L., Zhang, Y. W., Murphy, L., Tao, Y., Kong, X., Kang, B., Xia, L., Carvalho, F. L. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.008 · Cited by 122
Jiménez-Valerio, G., Martínez‐Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suárez, C., del Muro, X. G., Carles, J., Viñals, F., Graupera, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.015 · Cited by 120
Shen, S., Faouzi, S., Bastide, A., Martineau, S., Malka-Mahieu, H., Fu, Y., Sun, X., Mateus, C., Routier, É., Roy, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13360-6 · Cited by 120
Self-citationTET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
Puig, I., Tenbaum, S. P., Chicote, I., Arqués, O., Martínez‐Quintanilla, J., Cuesta-Borràs, E., Ramírez, L., Gonzalo, P., Soto, A., Aguilar, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96393 · Cited by 118
Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters
Umkehrer, C., Holstein, F., Formenti, L., Jude, J., Froussios, K., Neumann, T., Cronin, S. M., Haas, L., Lipp, J., Burkard, T. R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0614-0 · Cited by 106
Watson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91
Wang, L., Yang, Q., Peng, S., & Liu, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s212465 · Cited by 83
Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance
Goldman, A. J., Khiste, S., Freinkman, E., Dhawan, A., Majumder, B., Mondal, J., Pinkerton, A. B., Eton, E. O., Medhi, R., Chandrasekar, V., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aas8779 · Cited by 78
Fred Saad, C., & Fizazi, K. S. (2015) · Urology · doi:10.1016/j.urology.2015.07.034 · Cited by 71
Translational efficiency across healthy and tumor tissues is proliferation‐related
Hernandez‐Alias, X., Benisty, H., Schaefer, M. H., & Serrano, L. G. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199275 · Cited by 66
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
Sanduja, S., Feng, Y., Mathis, R. A., Sokol, E. S., Reinhardt, F., Halaban, R., & Gupta, P. B. (2016) · Oncogene · doi:10.1038/onc.2016.70 · Cited by 59
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance
Nouri, M., Caradec, J., Lubik, A. A., Li, N., Hollier, B. G., Takhar, M. M., Altamirano-Dimas, M., Chen, M., Roshan‐Moniri, M., Butler, M. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14850 · Cited by 59
Grassberger, C., McClatchy, D. M., Geng, C., Kamran, S. C., Fintelmann, F. J., Maruvka, Y. E., Piotrowska, Z., Willers, H., Sequist, L. V. D., Hata, A. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3652 · Cited by 53
Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death
Martins, I., Raza, S. Q., Voisin, L., Dakhli, H., Allouch, A., Law, F., Sabino, D., de Jong, D., Thoreau, M., Mintet, E., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0747-y · Cited by 52
Ribosome dependence of persister cell formation and resuscitation
Wood, T. K., Song, S., & Yamasaki, R. (2019) · The Journal of Microbiology · doi:10.1007/s12275-019-8629-2 · Cited by 47
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Aldonza, M. B. D., Ku, J., Hong, J., Kim, D., Yu, S. J., Lee, M.-S., Prayogo, M. C., Tan, S., Kim, D., Han, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aav7416 · Cited by 47
Fernando, T. M., Marullo, R., Gresely, B. P., Phillip, J. M., Yang, S. N., Lundell-Smith, G., Torregroza, I., Ahn, H., Evans, T., Győrffy, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1444 · Cited by 43
TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis
Baskar, R., Fienberg, H. G., Khair, Z., Favaro, P. M. B., Kimmey, S. C., Green, D. R., Nolan, G. P., Plevritis, S. K., & Bendall, S. C. (2019) · Life Science Alliance · doi:10.26508/lsa.201900554 · Cited by 14
Cited by
Gerstberger, S., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 913
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Glover, H. L., Schreiner, A., Dewson, G., & Tait, S. W. G. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01429-4 · Cited by 461
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Metadata
- Authors
- Shen, S., Vagner, S., & Robert, C.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 183
- Issue
- 4
- Pages
- 860-874
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3099461365
- Cited by
- 304
- References
- 123
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.